Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropivacaine Infusion Rates and Nerve Block Duration
NCT02801799Phase 1Terminated
- Sponsor
- Nordsjællands Hospital
- Start
- Oct 2016
- Primary completion
- Nov 2016
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ropivacaine hydrochloride liposomal suspension injection in postoperative pain (5 arms), sponsored by Nordsjællands Hospital. Primary endpoint: Duration of insensitivity towards cold at 24 hours. Started Oct 2016; status: terminated.
02
Drugs
ropivacaine hydrochloride liposomal suspension injection
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT02801799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02801799.